Durham, United Kingdom

Jonathan Charles Christian Atherton



Average Co-Inventor Count = 5.0

ph-index = 1

Forward Citations = 93(Granted Patents)


Location History:

  • Co Durham, GB (2014)
  • Durham, GB (2017 - 2021)

Company Filing History:


Years Active: 2014-2021

Loading Chart...
Loading Chart...
3 patents (USPTO):Explore Patents

Title: Innovations of Jonathan Charles Christian Atherton

Introduction

Jonathan Charles Christian Atherton is a notable inventor based in Durham, GB. He has made significant contributions to the field of chemistry, particularly in the development of purine derivatives. With a total of 3 patents to his name, Atherton's work has implications in pharmaceuticals and anti-tumor treatments.

Latest Patents

Atherton's latest patents include a process for preparing purine derivatives. This invention outlines a method that involves forming a reaction mixture with specific compounds and heating it to create a desired compound. The process also includes steps for isolating the compound and converting it into salt form. Another significant patent involves new crystalline forms of a purine derivative that exhibit excellent anti-tumor activity. This invention not only details the crystalline forms but also discusses their use in pharmaceutical compositions for disease prevention and treatment.

Career Highlights

Atherton is currently associated with Cyclacel Limited, a company focused on innovative cancer therapies. His work at Cyclacel has allowed him to explore and develop new chemical processes that contribute to advancements in medical treatments.

Collaborations

Some of his notable coworkers include Benjamin Mark Skead and Julian Scott Northen. Their collaborative efforts have likely enhanced the research and development processes within their projects.

Conclusion

Jonathan Charles Christian Atherton's contributions to the field of chemistry and pharmaceuticals are noteworthy. His innovative patents and work at Cyclacel Limited highlight his commitment to advancing medical science.

This text is generated by artificial intelligence and may not be accurate.
Please report any incorrect information to support@idiyas.com
Loading…